HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer

Christian Reinhard Mayr* (First author), Tobias Kiesslich (Co-author), Sara Erber, Dino Bekric, Heidemarie Dobias (Co-author), Marlena Beyreis (Co-author), Markus Ritter (Co-author), Tarkan Jäger (Co-author), Bettina Neumayer (Co-author), Paul Winkelmann, Eckhard Klieser (Co-author), Daniel Neureiter (Last author)

*Corresponding author for this work

Research output: Contribution to journalOriginal Article (Journal)peer-review

10 Citations (Web of Science)
Original languageEnglish
JournalCancers
Volume13
Issue number15
DOIs
Publication statusPublished - 31 Jul 2021

Keywords

  • HISTONE DEACETYLASE INHIBITOR
  • CARCINOMA-CELL-LINE
  • STEM-CELLS
  • CHOLANGIOCARCINOMA
  • ESTABLISHMENT
  • EXPRESSION
  • GROWTH
  • PROLIFERATION
  • TRICHOSTATIN
  • DEPSIPEPTIDE

Cite this